Nuvectis Pharma (NVCT) Set to Announce Quarterly Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) is expected to be releasing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Nuvectis Pharma to announce earnings of ($0.22) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:30 AM ET.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). On average, analysts expect Nuvectis Pharma to post ($1.01) EPS for the current fiscal year and ($1.10) EPS for the next fiscal year.

Nuvectis Pharma Stock Performance

NVCT stock opened at $18.49 on Tuesday. The company has a 50 day moving average price of $21.70 and a 200 day moving average price of $14.41. Nuvectis Pharma has a fifty-two week low of $5.55 and a fifty-two week high of $29.27.

Analysts Set New Price Targets

NVCT has been the topic of a number of recent research reports. UBS Group set a $33.00 price objective on Nuvectis Pharma in a research report on Monday, July 6th. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price target on shares of Nuvectis Pharma in a research note on Thursday, September 24th. Roth Capital raised their price target on Nuvectis Pharma from $20.00 to $33.00 and gave the company a “buy” rating in a report on Monday, July 6th. Cantor Fitzgerald began coverage on Nuvectis Pharma in a research report on Monday, August 24th. They issued an “overweight” rating for the company. Finally, Loop Capital set a $40.00 price objective on Nuvectis Pharma in a research report on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $36.25.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.